This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Adverse reactions

Authoring team

Adverse reactions

  • pain, swelling or redness at the injection site, low grade fever, malaise, shivering, fatigue, headache, myalgia and arthralgia are among the commonly reported symptoms after intramuscular or intradermal vaccination

  • a small painless nodule (induration) may also form at the injection site - these symptoms usually disappear within one to two days without treatment

  • nasal congestion/ rhinorrhoea, reduced appetite, weakness and headache are common adverse reaction following administration of LAIV

  • immediate reactions can occur
    • such as urticaria, angio-oedema, bronchospasm and anaphylaxis

The following adverse events have been reported very rarely after influenza vaccination over the past 30 years but no causal association has been established:

  • neuralgia, paraesthesia, convulsions and transient thrombocytopenia, vasculitis with transient renal involvement and neurological disorders such as encephalomyelitis (1)

Guillain-Barre syndrome as a result of vaccination against influenza is rare - about one case per million people inoculated (2).

Reference:

  • (1) The Green Book. Chapter 19 - Influenza (April 2019)
  • (2) NEJM 1998; 339: 1797-1802.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.